Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAI NASDAQ:BNTC NASDAQ:CAPR NASDAQ:GLUE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Beckley$4.09+1.0%$4.20$2.00▼$6.75$1.49B1.65.26 million shs3.96 million shsBNTCBenitec Biopharma$12.88+4.7%$11.85$9.85▼$16.76$422.56M0.2787,811 shs97,815 shsCAPRCapricor Therapeutics$29.60+0.9%$30.36$4.30▼$40.37$1.70B0.39949,465 shs794,685 shsGLUEMonte Rosa Therapeutics$20.71+10.9%$18.73$4.12▼$25.77$1.58B1.61.08 million shs1.75 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Beckley+0.99%-1.21%-5.32%+15.54%+102.48%BNTCBenitec Biopharma+4.72%+16.04%+14.69%+18.82%-11.60%CAPRCapricor Therapeutics+0.89%+13.63%+2.53%-1.00%+285.42%GLUEMonte Rosa Therapeutics+10.93%+16.61%+10.10%+31.83%+346.34%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Beckley$4.09+1.0%$4.20$2.00▼$6.75$1.49B1.65.26 million shs3.96 million shsBNTCBenitec Biopharma$12.88+4.7%$11.85$9.85▼$16.76$422.56M0.2787,811 shs97,815 shsCAPRCapricor Therapeutics$29.60+0.9%$30.36$4.30▼$40.37$1.70B0.39949,465 shs794,685 shsGLUEMonte Rosa Therapeutics$20.71+10.9%$18.73$4.12▼$25.77$1.58B1.61.08 million shs1.75 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Beckley+0.99%-1.21%-5.32%+15.54%+102.48%BNTCBenitec Biopharma+4.72%+16.04%+14.69%+18.82%-11.60%CAPRCapricor Therapeutics+0.89%+13.63%+2.53%-1.00%+285.42%GLUEMonte Rosa Therapeutics+10.93%+16.61%+10.10%+31.83%+346.34%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIAtai Beckley 2.91Moderate Buy$16.00291.20% UpsideBNTCBenitec Biopharma 2.56Moderate Buy$27.00109.63% UpsideCAPRCapricor Therapeutics 2.80Moderate Buy$48.3663.39% UpsideGLUEMonte Rosa Therapeutics 2.67Moderate Buy$32.5056.93% UpsideCurrent Analyst Ratings BreakdownLatest BNTC, ATAI, CAPR, and GLUE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026CAPRCapricor Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/10/2026BNTCBenitec Biopharma GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/8/2026ATAIAtai Beckley HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.005/26/2026ATAIAtai Beckley AegisSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/15/2026CAPRCapricor Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.005/13/2026CAPRCapricor Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.005/12/2026BNTCBenitec Biopharma EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$25.005/11/2026GLUEMonte Rosa Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)5/11/2026GLUEMonte Rosa Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$30.00 ➝ $31.004/20/2026BNTCBenitec Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ATAIAtai Beckley Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $15.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIAtai Beckley$4.09M368.17N/AN/A$0.69 per share5.93BNTCBenitec Biopharma$80K5,530.35N/AN/A$3.71 per share3.47CAPRCapricor Therapeutics$22.27M76.97N/AN/A$5.53 per share5.35GLUEMonte Rosa Therapeutics$123.67M14.15N/AN/A$3.58 per share5.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIAtai Beckley-$660.05M-$2.23N/AN/AN/A-19,019.44%-89.79%-63.58%8/13/2026 (Estimated)BNTCBenitec Biopharma-$37.92M-$1.14N/AN/AN/AN/A-34.82%-34.11%N/ACAPRCapricor Therapeutics-$105.04M-$2.32N/AN/AN/AN/A-59.27%-48.65%8/11/2026 (Estimated)GLUEMonte Rosa Therapeutics-$38.63M-$1.48N/AN/AN/A-302.69%-40.99%-25.94%8/6/2026 (Estimated)Latest BNTC, ATAI, CAPR, and GLUE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q3 2026BNTCBenitec Biopharma-$0.27-$0.24+$0.03-$0.24$4.55 millionN/A5/12/2026Q4 2025ATAIAtai Beckley-$0.11-$0.08+$0.03-$0.08$0.22 million$0.95 million5/12/2026Q1 2026CAPRCapricor Therapeutics-$0.55-$0.59-$0.04-$0.59$40.00 millionN/A5/7/2026Q1 2026GLUEMonte Rosa Therapeutics-$0.3882-$0.45-$0.0618-$0.45$10.95 million$4.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATAIAtai BeckleyN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/ACAPRCapricor TherapeuticsN/AN/AN/AN/AN/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIAtai Beckley0.027.907.90BNTCBenitec BiopharmaN/A56.8256.82CAPRCapricor TherapeuticsN/A8.428.42GLUEMonte Rosa TherapeuticsN/A9.549.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIAtai Beckley28.41%BNTCBenitec Biopharma52.19%CAPRCapricor Therapeutics21.68%GLUEMonte Rosa Therapeutics79.96%Insider OwnershipCompanyInsider OwnershipATAIAtai Beckley26.80%BNTCBenitec Biopharma4.80%CAPRCapricor Therapeutics9.20%GLUEMonte Rosa Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIAtai Beckley80368.17 million269.50 millionOptionableBNTCBenitec Biopharma2034.35 million32.71 millionNo DataCAPRCapricor Therapeutics10157.91 million52.58 millionOptionableGLUEMonte Rosa Therapeutics9084.48 million79.07 millionOptionableBNTC, ATAI, CAPR, and GLUE HeadlinesRecent News About These CompaniesMonte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 7.8% - Should You Buy?June 23 at 12:59 PM | marketbeat.comMonte Rosa Therapeutics (NASDAQ:GLUE) COO Sells $41,344.00 in StockJune 21 at 5:22 AM | americanbankingnews.comMonte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $57,000.00 in StockJune 21 at 4:42 AM | americanbankingnews.comMonte Rosa Therapeutics (NASDAQ:GLUE) COO Jennifer Champoux Sells 2,176 SharesJune 19, 2026 | insidertrades.comBVF Inc. IL Decreases Stock Holdings in Monte Rosa Therapeutics, Inc. $GLUEJune 18, 2026 | marketbeat.comMonte Rosa Therapeutics, Inc. $GLUE Shares Sold by Baker BROS. Advisors LPJune 18, 2026 | marketbeat.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $32.50 Average Price Target from BrokeragesJune 13, 2026 | americanbankingnews.comMonte Rosa Therapeutics, Inc. $GLUE Shares Sold by Alphabet Inc.June 13, 2026 | marketbeat.comMonte Rosa: Initiating Coverage With A Buy On Degrader Platform PotentialJune 11, 2026 | seekingalpha.comMonte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to BuyJune 3, 2026 | finance.yahoo.comMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2026 | globenewswire.comMonte Rosa Therapeutics (NASDAQ:GLUE) COO Jennifer Champoux Sells 2,175 SharesMay 29, 2026 | insidertrades.comPiper Sandler Sticks to Their Buy Rating for Monte Rosa Therapeutics (GLUE)May 22, 2026 | theglobeandmail.comMonte Rosa Therapeutics to Participate in Upcoming Investor ConferencesMay 20, 2026 | globenewswire.comDegron adds $40M to series A, supporting immunology plans for molecular glue platformMay 16, 2026 | biospace.comBMonte Rosa Trial Progress And Valuation Gap Draw Investor AttentionMay 11, 2026 | finance.yahoo.comMonte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2026 | zacks.comMonte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business UpdatesMay 7, 2026 | globenewswire.comMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 5, 2026 | globenewswire.comMonte Rosa Therapeutics, Inc. (GLUE) Presents at AACR Annual Meeting 2026 - SlideshowApril 23, 2026 | seekingalpha.comMonte Rosa Therapeutics (NASDAQ:GLUE) Gains Biotech SpotlightApril 22, 2026 | kalkinemedia.comKNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBNTC, ATAI, CAPR, and GLUE Company DescriptionsAtai Beckley NASDAQ:ATAI$4.09 +0.04 (+0.99%) Closing price 06/23/2026 03:58 PM EasternExtended Trading$4.09 +0.00 (+0.02%) As of 05:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Benitec Biopharma NASDAQ:BNTC$12.88 +0.58 (+4.72%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$12.40 -0.48 (-3.69%) As of 06/23/2026 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Capricor Therapeutics NASDAQ:CAPR$29.60 +0.26 (+0.89%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$30.07 +0.47 (+1.58%) As of 05:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Monte Rosa Therapeutics NASDAQ:GLUE$20.71 +2.04 (+10.93%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$21.17 +0.46 (+2.22%) As of 04:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
